



**Review Article**

**ARTIFICIAL INTELLIGENCE IN PHARMACY**

Sarojini Nayak<sup>1</sup>, Durga Madhab Kar<sup>2</sup>, N Saroj Kumar Choudhury<sup>3</sup>

Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela, Odisha<sup>1</sup>

Siksha 'O' Anusandhan, Bhubaneshwar, Odisha<sup>2</sup>

SCB Medical College Hospital (Pharmacy), Cuttack, Odisha<sup>3</sup>.

**ARTICLE INFO**

Date of submission:

12.07.2023

Date of Revision:

25.07.2023

Date of acceptance:

03.08.2023

**Key Words:**

Artificial  
Intelligence, Drug  
discovery,  
Formulation  
development for  
drug delivery  
Hospital pharmacy,  
Multidrug  
pharmacology

**ABSTRACT**

AI's objective is to develop intelligent modelling that supports knowledge visualisation, issue solving, and decision-making. It has the power to improve failing healthcare systems with new efficiency, medications, diagnostics, and economics in the ever-evolving environment we live in. Artificial intelligence (AI) is the capacity of a computer-controlled robot or digital computer to carry out tasks normally performed by intelligent people. Automation, software, and computer programs have all been developed to assist and streamline healthcare procedures. These incorporate indicative advances like X-ray, Radiation innovation, CT diagnostics, Mechanical medical procedure and some more. AI has advanced significantly in the field of healthcare, playing important roles in the administration and storage of data and information, including patient medical histories, drug inventories, sales records, and so on. AI has lately risen to prominence in a variety of pharmacy-related fields, such as drug discovery, developing drug delivery formulations, hospital pharmacy, customised medication, and multi drug pharmacology.

©2020 Published by HOMES on behalf of RJPLS

This is an open access article under the CC-BY-NC-ND License.

**\*Corresponding author**

Sarojini Nayak

Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela, Odisha<sup>1</sup>

## **Introduction:**

The study of clever computer programs that learn from data in a manner analogous to human attention is known as artificial intelligence (AI)<sup>[1]</sup>. This process typically entails gathering data, developing efficient strategies for making use of that data, displaying precise or approximate findings, and making self-corrections or adjustments<sup>[2]</sup>. Man-made intelligence is commonly used to dissect AI to emulate the mental elements of individuals<sup>[2,3]</sup>. Using AI, more precise analyses and useful interpretations can be obtained<sup>[3]</sup>. Because AI can examine vast amounts of data from many different modalities, there are prospects for it to be used in pharmaceutical and healthcare research<sup>[4]</sup>. The application of AI in healthcare and other fields is the subject of several recent studies in great detail. AI (ML), natural language handling (NLP), actual robots, mechanical cycle robotization, and so forth. are a few of the AI technologies that are utilized in the healthcare industry<sup>[5]</sup>. Brain network models and profound learning are utilized in AI to find clinically significant viewpoints in imaging information at a beginning phase, eminently in malignant growth related conclusion<sup>[6,7]</sup>. Computer programs are used in NLP to comprehend and interpret spoken language. As of late, ML procedures are overall generally utilized in NLP for exploring unstructured

information in data sets and keeps as specialist's notes, lab reports, and so on. by planning the essential data from various symbolism and text based information that guides in dynamic in conclusion and treatment choices<sup>[8]</sup>. Platforms that may leverage a number of data sources, including as patient-reported symptoms, biometrics, imaging, biomarkers, etc., have been recognised as AI-based solutions. As a result of the capacity to identify probable illnesses early on made possible by AI developments, there is a higher likelihood that they can be prevented. Several areas of healthcare, such as nursing, telemedicine, housekeeping, imaging, surgery, rehabilitation, etc., employ physical robots<sup>[9,10]</sup>. Robotic process automation makes use of technology that is low-cost, simple to programme, and capable of carrying out organised digital chores for administrative needs while acting as a semi-intelligent system user. Using this together with image recognition is another option. The healthcare system may make use of this technology for repetitive tasks like updating patient records and billing<sup>[11]</sup>. Due to its extensive applicability across all phases, AI cannot be disregarded while focused on the pharmaceutical industry. It is clear that AI has an impact on pharmaceutical goods at every level, from medication development through product management.

Due to the widespread applications of AI in the healthcare and pharmaceutical industries, this review included articles on the use of AI in disease diagnosis, drug discovery, developing drug delivery formulations, hospital pharmacy, clinical trials, individualized treatment, and multidrug pharmacology. All of the studies are searched on websites like PubMed, Science Direct, and Google Scholar with specific keywords. The following topics were covered in this review's discussion on artificial intelligence (AI).

1. Disease diagnosis

2. Drug discovery:

- Target identification with AI
- Lead optimization with AI
- Clinical trials using AI
- Relevant AI based drug detection researcher

3. Formulation development for drug delivery

- Dispersions of solid
- Micro emulsion and emulsion
- Tablet
- Multiparticulate material

4. Healthcare pharmacy

5. Digital therapy and individualized care:

- Radiotherapy
- Retina with man-made intelligence
- Malignant growth with simulated intelligence
- Other ongoing illnesses and simulated intelligence

6. Multidrug pharmacology

### **Classification of AI:**

Depending on their existence and quality, AI can be divided into two categories. Based on their capabilities, AI can be divided into the following groups:

i) Weak AI or Artificial Narrow Intelligence (ANI): It can only do a limited number of things, like recognize faces, steer a car, play chess, and read traffic signals, among other things.

ii) Artificial General Intelligence (AGI), also referred to as Strong AI, is a type of artificial intelligence that is capable of performing all human-level tasks. It can work on human insight and empower finishing of testing undertakings.

iii) Artificial Genius (ASI): This innovation is more brilliant than people and is a lot more occupied than them regarding painting, math, and different subjects like space.

Computer based intelligence might be separated into the accompanying classes relying upon regardless of whether they are now existing.

i) Type 1: Because it lacks a memory system, it is used for applications with a limited scope that cannot use prior knowledge. It is known as a "reactive machine." Instances of this memory incorporate an IBM chess program that can gauge moves and perceive the checkers on the chessboard.

ii) Type II: It has limited memory and can use prior knowledge to solve various problems. In the decision-making systems of automated cars, certain recorded observations are used to record subsequent actions; however, these recordings are not kept forever.

iii) Type 3: It is predicated on the "Hypothesis of Psyche". It proposes that individuals' exceptional perspectives, inspirations, and wants impact the choices they make. In this system, there is no AI.

iv) Type 4: It has a sense of self and is conscious of itself, or self-aware. This is yet another AI system that does not exist <sup>[12]</sup>.

#### **An overview of AI:**

The terms "AI," also known as "machine intelligence," and "robotics" are frequently used interchangeably. While robotics is simply the design of machines that can perform challenging, repetitive tasks, AI is the display of human-like behaviours or intelligence by any computer or machine <sup>[13]</sup>. In a process known as automation, robots may be able to move or transport things on their own with the help of a predefined program and surface sensors. However, robots were never designed to have these "intelligent capabilities." Fundamentally, simulated intelligence is the part of software engineering that spotlights on building keen PCs equipped for doing position that would commonly be performed by people <sup>[14]</sup>. Digital computers

and computer-controlled robots that can perform the same intellectual and cognitive functions as humans are frequently made with the help of artificial intelligence (AI). These intellectual and cognitive processes include, among others, language, logical thinking, problem-solving, and perception. It is also referred to as weak AI or narrow AI due to the fact that the type of AI currently in use is only intended to perform specific tasks like searching the internet, recognizing faces and voices, controlling automobiles, and so on. The creation of computers that are capable of independently surpassing humans at all cognitive activities is the long-term goal of the artificial intelligence (AI) community. The overall computer based intelligence, otherwise called solid computer based intelligence (ADI), plans to assemble robots that are fit for completing all mental capabilities related with people.

AI is the phrase used to describe a machine's or computer's capacity to think, act, behave, and perform like a person. The SIRI feature on Apple's iPhone <sup>[15]</sup>, Alexa on Amazon <sup>[16]</sup>, and self-driving cars made by Google, Mercedes, BMW, and Tesla, to mention a few <sup>[17]</sup>, are all well-known instances of AI-controlled systems. Knowledge Engineering, which involves equipping robots with access to a wealth of facts and information about the human environment so they can replicate human

behaviour, might be considered the foundation of AI. Another form of AI is called "machine learning," which uses statistical models and algorithms to increase software applications' predictive accuracy without explicitly being programmed. It was established on the reason that robots can gain from information, perceive issues, and make decisions with minimal measure of help or human support. Self-driving Google vehicles, extortion location, and online proposal administrations like those on Amazon and Netflix are instances of uses for AI [18].

There has been a variety of scepticism, criticism, and misconceptions about AI, mainly in relation to safety and the risks that can be amplified by the development of robots with cognitive capacities comparable to those of humans. One of Forbes' five predictions for AI in 2019 is that it may become a political problem. Certain individuals have raised stresses that the advancement of computer based intelligence frameworks that are more brilliant than people through broad man-made intelligence may be all the more destructive and mean certain doom for the human species itself, notwithstanding stresses that AIs might be utilized as weapons of war and mass destruction. Because we may not be able to anticipate how AI systems that are smarter than us

would act, they believe that humans may end up being influenced by these extremely intelligent robots. The majority of safety concerns regarding such systems may be alleviated, according to scientists, if the "goals" of future super intelligent AI systems can be designed to align with human goals [19].

### **1. Diagnoses and illnesses:**

The severity of a patient's illness burden should be taken into consideration while classifying them, and AI can play a significant role in diagnosis [20]. When one has a diagnosis, their ailment is given a name based on specific antecedent issues [21]. It is usually advisable to keep track of each patient's health report forms in order to compile the majority of evaluations that come from conducting exams and tests. The right decisions are made based on information gathered, primarily in relation to the medical requirements for a prompt diagnosis. The analysis is solely at the physicians' discretion and is subject to change [22]. Deep learning, neural networking, and algorithms are now widely used in technology to identify, extract, and cater to all the collected data [23,24,25,26,27]. The two main disorders where AI has gained relevance are cancer and dementia [28,29]. Unsupervised learning can be used to diagnose hepatitis [30]. However, by making numerous evolutionary adjustments and modifying expectations, deep learning

correlations may be attained [31,32]. Larger data sets and diverse entries often help AI's appropriateness [31,33], but the results are sometimes unintelligible [34,35]. Deep learning in diagnostics has several applications, including the categorization of dermatological illnesses [36] and the identification of atrial fibrillation [37]. For the estimation of algorithms, cross-validation can be employed to randomly partition data into numerous groups [38]. The typical metrics of AI place special emphasis on three crucial areas: accuracy, sensitivity, and specificity [39,40]. Predictive modelling was the subject of several research, which were evident in their ability to forecast the onset of Parkinson's disease [41]. For the purpose of diagnosing lung disorders, the rib segmentation algorithm was created utilising the chest X-ray pictures. Due to a number of drawbacks, traditional approaches are not effective for rib-wise segmenting X-ray pictures. In this study, an algorithm was created by adding unpaired samples to chest X-ray pictures of pneumonia patients. A multi-scale network then learned the properties of the images. According to the study, this method performs well with improved rib segmentation and may be helpful in the diagnosis of lung cancer and other lung disorders [42]. Researchers have recently employed algorithms and machine learning to classify and identify heart arrhythmias by

analysing ECG data. [43]. In a different study, the support vector machine (SVM) classifier and optimisation genetic algorithm (GA) were used to categorise and diagnose tuberculosis [44].

## **2. Drug discovery:**

The identification and validation of therapeutic targets, the optimisation of lead compounds, and the assessment of drug effectiveness and safety are all steps in the lengthy and difficult process of drug development. treatment development has traditionally depended on trial and error, with researchers testing several chemicals in the hopes of identifying a promising treatment candidate. However, this procedure can be cumbersome and ineffective, and some medication candidates may not advance past the preclinical stage. Various stages of drug discovery, including target identification and preclinical and clinical development, can benefit from the application of AI.

### Target identification with AI:

Finding novel therapeutic targets, which are biological processes or molecules implicated in a disease process, is an important first step in the drug development process. Large databases of molecular and biological data may be analysed using artificial intelligence (AI), revealing previously undiscovered or ignored therapeutic targets. Algorithms that use machine learning can recognise patterns in

existing data to forecast which objectives have the highest chances of achievement.

Lead optimisation with AI:

Researchers must create compounds that can interact with a target and have a therapeutic impact after a promising pharmacological target has been found. By anticipating their characteristics and enhancing their structure, AI can aid in the optimisation of these compounds. For instance, depending on a molecule's structure, machine learning algorithms may forecast a substance's solubility, stability, and bioavailability. They can also forecast if a chemical will be harmful or have negative side effects. By finding potential leads early on and lowering the number of compounds that need to be synthesised and evaluated, this can save time and money.

A few common uses of AI in drug discovery include virtual screening <sup>[45]</sup>, de novo drug design <sup>[46]</sup>, retro synthesis and reaction prediction <sup>[47]</sup>, and de novo protein design <sup>[48]</sup>, which may be divided into two categories: predictive and generative tasks. Researchers may use AI to examine enormous volumes of data and forecast which compounds have the best chance of succeeding in clinical trials. Researchers are using AI to improve the design of clinical trials and find novel therapeutic targets.

Clinical Trials Using AI:

Clinical trial optimisation is another area in which AI may be very helpful. AI enables researchers to create more successful and economical clinical trials by assessing patient data and identifying patient subgroups most likely to benefit from a specific medication. This can increase the likelihood of success while cutting down on the time and expense of clinical studies. AI may be used to spot possible safety issues early on, giving researchers the opportunity to change the trial's design or end it if required.

Relevant AI based drug detection researches:

1. Researchers at the University of California, San Francisco employed artificial intelligence (AI) in 2021 to find prospective new pharmaceuticals for COVID-19 treatment. Over 1 billion chemicals were screened by the researchers using a machine learning system to find those that can potentially suppress the SARS-CoV-2 virus.

2. A novel kidney disease medicine was created in 2020 by Cambridge University researchers using AI. The 3D structure of the disease-related protein was examined using a deep learning algorithm by the researchers, who then utilised this knowledge to create a chemical that may attach to the protein and inhibit its function.

3. Researchers at the University of North Carolina at Chapel Hill employed AI in

2019 to create brand-new drugs that may be able to fight germs that are resistant to antibiotics. In order to build novel antibiotics with diverse chemical structures, the researchers first utilised a machine learning algorithm to analyse the chemical structures of well-known antibiotics and find common patterns.

4. AI was utilised by Stanford University researchers in 2018 to forecast the activity of possible cancer therapy medication candidates. The deep learning method was used by the researchers to analyse the chemical make-up of well-known cancer medicines and forecast the activity of novel molecules.

### **3. Formulation development for drug delivery:**

Drug delivery system development using AI methods:

Designing drug delivery systems typically comes with some drawbacks, such as the inability to forecast the link between formulation parameters and reactions [49,50]. Both the outcomes of the treatment and the unforeseen events are connected to this. Many different kinds of intelligent drug releasing systems are designed with on-demand dosage adjustment, rates of drug release, targeted releasing, and drug stability in mind. With regard to self-monitoring systems for drug release, the appropriate algorithms are helpful for managing the quantity and duration of drug

release [51]. Consequently, AI methods are useful for predicting the potential for drug delivery of drug delivery dosage forms and the efficacy of medication dosing [49].

Dispersions of solids:

Utilizing poloxamer 188 and Soluplus, solid carbamazepine dispersions have been produced through the use of ANN modelling and experimental design. [52] Solid carbamazepine dispersions were made to improve carbamazepine's solubility and dissolution rate. The solvent casting technique was used to create these carbamazepine-Soluplus-poloxamer 188 solid dispersions. In order to maximize drug dissolution rate, ANN modelling (feed-forward back propagation) with the logistic sigmoid activation function has already been used in a study to examine the relationships between various factors and drug dissolution characteristics. The solid drug dispersions in this study were made by using poly (vinyl pyrrolidone)/polyethylene glycol combinations as carriers. The utilized ANN-assisted modelling accurately predicted pharmaceutical solid dispersion preparations with the necessary dissolving characteristics and long-term physical stability [53].

Micro emulsions and emulsions:

ANNs have also been used to generate stable oil-in-water emulsion formulations. In this paper, the optimisation of the fatty



alcohol content to create oil/water emulsions was examined. The concentrations of lauryl alcohol and time were the unreliable variables (factors) studied in this paper. The reliable variables (responses) were conductance, viscosity, zeta potential, and droplet size. Based on validation testing, it was discovered that ANN-predicted values had a strong connection to the experiment's results [54]. ANNs have likewise been utilized in the plan of miniature emulsions, where it was easy to dissect the forecast of accuracy in view of the idea of the miniature emulsion from the formula [55]. Inside primary properties and the kind of the miniature emulsion have likewise been precisely anticipated utilizing a blend of hereditary calculations and developmental ANNs. ANN modelling has previously been used to predict the oral formulation of stable micro emulsions containing antitubercular medications like rifampicin and isoniazid [56].

#### Tablets:

Static and dynamic ANNs have been utilized in the plan of lattice tablets to display the dissolving profiles of different framework tablets. In this work, Monte Carlo simulations and the genetic algorithm optimizer tool were utilized for these ANN-based modelling. The Elman dynamic brain organizations and choice trees were utilized by the specialist to precisely figure the

dissolving attributes of hydrophilic and lipid-based network tablets with directed medicine discharge designs. In contrast to the majority of commonly used multilayer perceptron and static networks, the Elman neural networks-based modelling demonstrated the effective modelling of drug releasing patterns by various formulas of hydrophilic as well as lipid-based matrix tablets [57]. Metformin HCl matrix tablets for sustained release were created in a study using a multilayer perceptron and feed forward back propagation approach [58]. To create the optimised formulations, the matrix tablets' in vitro metformin HCl release pattern was optimised. The independent variables (factors) and dependable variables (responses) were examined for network training. In addition, the model was validated through numerous trials using the leave-one-out strategy.

Multiparticulate materials, including beads, micro particles, and nanoparticles:

Multiparticulate verapamil beads were created using CAD/Chem software-aided modelling. The impacts of various detailing and cycle factors on the in vitro verapamil discharge by the dabs were analysed in this review. When contrasted with the expected results delivered by the ANN displaying, the in vitro verapamil delivering information for the streamlined dots were found to be in great arrangement [59]. To increase stability and site-specific release,

ANN modelling was used in a study to determine how process factors affected papain (an enzyme) entrapment within alginate-based beads<sup>[60]</sup>.

#### **4. Healthcare pharmacy:**

In the hospital-based health care system, AI is used in a variety of ways, such as organizing dosage forms for specific patients and selecting appropriate or readily available administration methods or treatment guidelines.

Keeping up with medical records:

It is difficult to keep track of medical records for patients. The AI system makes data collection, storage normalization, and tracing simpler. The Google project on emotional well-being<sup>[61]</sup> (made by Google) serves to remove the clinical records rapidly. Subsequently, this drive is advantageous for giving faster and better medical services. The Moor Fields Eye Hospital NHS's eye care will benefit from this initiative.

Creating a treatment plan:

It is possible to develop efficient treatment plans by making use of AI technology. When a patient experiences a severe state and it becomes difficult to select an appropriate treatment plan, the AI system must maintain control. This technology's treatment plan takes into account all of the previous reports, data, and clinical information. IBM's Watson for Oncology<sup>[62]</sup>, A cognitive computing decision

support system is provided as a software as a service that compares patient data to thousands of previous cases and utilizes information gathered from collaborating for thousands of hours with doctors at Memorial Sloan Kettering Cancer Center. After that, it provides oncology clinicians with treatment options to help them make decisions. Memorial Sloan Kettering gathered over 300 medical articles, 200 textbooks, and approximately 15 million pages of text to support these therapy options<sup>[62]</sup>.

Helping with routine duties:

Moreover, computer based intelligence innovation assists for certain monotonous positions, for example, breaking down X-ray pictures, radiography, Reverberation, ECG, and so on. to find and analyse ailments or anomalies. An IBM calculation called Clinical Sieve<sup>[63]</sup> is a "mental partner" major areas of strength for with and logical abilities. A medical start-up is needed to use deep learning and medical data to improve the patient's condition. For each substantial part, there is a specific PC program that is utilized specifically disease circumstances. For almost all imaging tests, such as X-ray, CT, ECHO, ECG, etc., profound learning might be utilized.

Assistance with drugs and health support:

In recent years, it has been acknowledged that the use of AI technology for pharmaceutical assistance and health

support services is effective. Molly, a start-up's virtual nurse, has a kind voice and appearance [64]. Its purpose is to assist patients with chronic diseases in directing their own care and to support them during medical appointments. AI Therapy [65] is a smartphone webcam app that keeps tabs on patients and helps them manage their diseases. Individuals who take part in clinical trials and individuals with serious drug issues can both benefit from this app.

#### Medical precision:

The influence of AI on genetic evolution and genomics is positive. An AI system called Deep Genomics [66] is helpful for identifying patterns in genomic data and medical records that relate certain mutations to specific illnesses. This technique provides clinicians with information on what happens within a cell when genetic variation modifies DNA. The inventor of the human genome project, Craig Venter [67], created an algorithm that uses DNA to provide details on a patient's physical traits. To pinpoint the precise site of cancer and vascular disorders in their early stages, "Human Longevity" AI technology is helpful.

#### Creation of drugs:

Pharmaceutical research & development takes more than ten years and costs billions of dollars. To identify the treatments from

the database of molecular structure, "Atom wise"[68], an AI tool that makes use of supercomputers, is helpful. It launched a virtual search programme for a secure and productive treatment for the Ebola virus using already available medications. The technique found two medications that contributed to the spread of the Ebola virus. Compared to manual analysis, which may take months or even years, this study was finished in a single day. Big data was created by a Boston-based biopharma business for patient management. Data is held back to determine the causes of some patients' illness survival. To distinguish between meteorological circumstances that are healthy and those that are conducive to sickness, researchers employed biological data from patients and AI technology. It supports the development of applications for problem-solving, healthcare, and drug discovery.

Using AI in the healthcare system benefits patients:

In 2016, one of the top 10 most promising technologies was the "open AI ecosystem"[69]. The information gleaned via social awareness algorithms should be collected and compared. In the healthcare system, a large amount of data is logged, including patient medical histories and treatment information going back to infancy. Ecosystems can analyse this vast amount of data and provide

recommendations regarding the patient's behaviours and way of life.

Analysing the healthcare system:

If every piece of information in the healthcare system is computerised, retrieving information will be simple. 97% of the bills in the Netherlands are kept digitally [70], and they include information on the treatments received as well as the identities of the hospitals and doctors who provided them. As a result, they are simple to recover. Local business Zorgprisma Publiek uses IBM Watson cloud technology to examine the invoices. If a mistake is made, it notices it right away and acts appropriately. As a result, it enhances and decreases the need for patient hospitalisation.

#### **5. Digital therapy/individualized care:**

From the raw datasheets, AI can extract a significant association that can be used for diagnosis, treatment, and illness mitigation. There is the possibility to apply a wide range of more recent computational understanding approaches in virtually every area of medical science. The task of gathering, evaluating, and using extensive knowledge is required to tackle the complicated clinical issues. The advancement of medical AI has aided physicians in the resolution of challenging clinical issues. The medical care experts can find support from frameworks like fake brain organizations (ANNs), transformative

calculation, fluffy master frameworks, and mixture insightful frameworks to deal with the information [71]. The biological nervous system serves as the foundation for the ANN system [72]. In order to process data in parallel, a network of linked computer processors known as neurons is used. A binary threshold function was used to create the first artificial neuron [73]. The most common model included many layers, including input, middle, and output. It was called a multilayer feed-forward perceptron. Every neuron is linked together by connections with a certain numerical weight [74].

Radiotherapy:

The clinical recommendations can be applied by a straightforward automated computer programme using structures. The treatment planning system is capable of analysing the patient's anatomy and physiology as well as simulating the thought process that is often used in manual therapy planning. The accuracy of three-dimensional dose distribution and dosage models for spatial dose is encouraging [75]. With the use of many imaging biomarkers, radiation oncology may provide comprehensive information on tumours. Radiomics can be used to predict treatment results and side effects for specific individuals receiving radiation therapy [76].

Retina with AI:

High-resolution retinal imaging has made it significantly easier to evaluate people's health. With the use of high-definition medications, an ophthalmologist or radiologist may design a specific therapy and create an ever-improving learning healthcare system. Highly personalised data can be extracted from a single retinal image [77].

#### Cancer and AI:

Man-made intelligence assists with disease recognition by accelerating the cycle while keeping up with high exactness. Artificial intelligence based PET imaging of lymphoma is utilized to survey growth trouble, which is then utilized to portray the cancer, measure heterogeneity, and figure treatment reaction [78].

On account of gastrointestinal disease, colorectal malignant growth (CRC) screening innovation is used to evaluate the danger in patients [79] and visual night time imaging plays a huge part in foreseeing the headway of gastric malignant growth [80]. Early detection can slow the spread of cancer with accurate blood testing, endoscopic imaging, and AI [79]. However, because blinded controlled experiments and adequate randomization are lacking in AI, only retrospective evidence can be collected [81]. Additionally, there have been trials where the cancer prognosis could not be supported by the prediction models. Later on, various models like the Random

Survival Forest Algorithm, the Cox Survival Regression Algorithm, and the Multi-Task Logistic Regression Algorithm have become more complicated and are now more likely to be predictive [82]. With these turns of events, gastroenterology has mechanized the conclusion of danger, for classification as well as for location and amplification using endocytoscopy, which hasn't been utilized in real practice [83].

#### Other chronic diseases and AI:

Based on methods used in computer programming, several computerised treatments are available. Multiple-choice questions or joysticks are employed in the behavioural and cognitive approach that is the emphasis of the treatments [84]. An innovative form of computer interaction called intelligent computer-assisted instruction has recently been developed. It can possibly utilize other simulated intelligence innovations like regular language understanding and master frameworks [85], and with its assistance, one can make a mix treatment in light of the patient's own biopsy and take on n-of-1 medicine proposals. Normal checking is fundamental for persistent illnesses, and with the utilization of man-made brainpower, this observing might be completed by virtual clinical aides. This kind of support has been implemented by a lot of businesses. It often provides text-based virtual coaching through mobile apps

and uses AI to make dietary recommendations based especially on the gut microbiota. a deep learning-based integrated system [86]. A smart watch, accelerometer data from physical activity, and a single-lead ECG sensor can all be used to predict arterial fibrillation. In the treatment of diabetes, case-based thinking, which was made using simulated intelligence innovation, is generally utilized [87].

### **6. Multi-drug pharmacology:**

For the high level acknowledgment of obsessive cycle in numerous sicknesses at their sub-atomic establishment, the "one illness different targets" worldview now leads over the "one sickness one targets" approach multidrug pharmacology is the investigation of "one-infection various targets" phenomena [88]. There are numerous useful data sets accessible for the accomplishment of an assortment of significant and valuable data connected with the construction of precious stones, synthetic highlights, organic properties, sub-atomic pathways, restricting affinities, infection concern, drug targets, and so on. Models incorporate PubChem, KEGG, ChEMBL, ZINC, Line, Ligand Exhibition, PDB, Medication bank, Super objective, Restricting DB, and so on. The data sets expected to portray multidrug pharmacological mixtures and specialists

are additionally found with the utilization of artificial intelligence.

### **Conclusion:**

In terms of awareness, efficacy in delivering treatment, identification of impending issues, accurate sickness diagnosis in advance, and most recent methods for therapies, healthcare has evolved as a result of the introduction of more cutting-edge and new generation AI technology. The application of AI technology to the study and comprehension of a number of significant facets of pharmacy, such as drug development, dosage form design, poly pharmacology, hospital pharmacy, and other related topics has received a lot more attention in recent years. This is because technology advancements in AI imitate human thought processes and decision-making processes. Current applications of AI algorithms in healthcare include accurate patient monitoring, drug research trials, early illness detection, and self-care. India would invest US\$11.78 billion in its primary sector AI by 2025, raising its GDP by US\$1 trillion by 2035, according to figures. AI has revolutionary consequences in a number of industrial, intellectual, and social applications, well beyond the effects of prior industrial revolutions. Additionally, AI decision-making has beaten human judgement in a number of fields.

## REFERENCES:

1. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug discovery today*. 2019 Mar 1;24(3):773-80.
2. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. *Advanced drug delivery reviews*. 2019 Nov 1;151:169-90.
3. Russell S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence. *AI magazine*. 2015 Dec 31;36(4):105-14.
4. Toepper M. Dissociating normal aging from Alzheimer's disease: a view from cognitive neuroscience. *Journal of Alzheimer's disease*. 2017 Jan 1;57(2):331-52.
5. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future healthcare journal*. 2019 Jun;6(2):94.
6. Fakoor R, Ladhak F, Nazi A, Huber M. Using deep learning to enhance cancer diagnosis and classification. In *Proceedings of the international conference on machine learning 2013 Jun* (Vol. 28, pp. 3937-3949). New York, NY, USA: ACM.
7. Vial A, Stirling D, Field M, Ros M, Ritz C, Carolan M, Holloway L, Miller AA. The role of deep learning and radiomic feature extraction in cancer-specific predictive modelling: a review. *Transl Cancer Res*. 2018 Jun 1;7(3):803-16.
8. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, Cui C, Corrado G, Thrun S, Dean J. A guide to deep learning in healthcare. *Nature medicine*. 2019 Jan;25(1):24-29.
9. Hussain A, Malik A, Halim MU, Ali AM. The use of robotics in surgery: a review. *International journal of clinical practice*. 2014 Nov;68(11):1376-82.
10. Khan ZH, Siddique A, Lee CW. Robotics utilization for healthcare digitization in global COVID-19 management. *International journal of environmental research and public health*. 2020 Jun;17(11):3819.
11. Ribeiro J, Lima R, Eckhardt T, Paiva S. Robotic process automation and artificial intelligence in industry 4.0—a literature review. *Procedia Computer Science*. 2021 Jan 1;181:51-58.
12. Das S, Dey R, Nayak AK. Artificial intelligence in pharmacy. *Indian Journal of Pharmaceutical Education and Research*. 2021 Apr 1;55(2):304-18.
13. Honavar V. Artificial intelligence: An overview. *Artificial Intelligence Research Laboratory*. 2006:1-4.
14. Lopes V, Alexandre LA. An overview of blockchain integration with robotics and artificial intelligence. *arXiv preprint arXiv:1810.00329*. 2018 Sep 30.

15. SIRI. [cited 2022 20 May]; Available from: <https://www.techtarget.com/searchmobilecomputing/definition/Siri>.
16. 11. What Is Alexa? [cited 2022 20 May]; Available from: <https://itchronicles.com/artificial-intelligence/is-alexana/#:~:text=What%20Is%20Alexa%3F,Echo%20and%20Dot%20smart%20speakers>
17. How Google's Self-Driving Car Will Change Everything. [cited 2022 20 May]; Available from: <https://www.eescorporation.com/do-self-driving-cars-useai/>
18. Das S, Dey A, Pal A, Roy N. Applications of artificial intelligence in machine learning: review and prospect. *International Journal of Computer Applications*. 2015 Jan 1;115(9).
19. State Of AI And Machine Learning In 2019.; Available from: <https://www.forbes.com/sites/louiscolombus/2019/09/08/state-of-ai-and-machine-learning-in2019/?sh=133dd64c>.
20. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. *New England Journal of Medicine*. 1978 Oct 26;299(17):926-30.
21. Jutel A. Sociology of diagnosis: a preliminary review. *Sociology of health & illness*. 2009 Mar;31(2):278-99.
22. Chang CL, Hsu MY. The study that applies artificial intelligence and logistic regression for assistance in differential diagnostic of pancreatic cancer. *Expert Systems with applications*. 2009 Sep 1;36(7):10663-72.
23. Nasirian F, Ahmadian M, Lee OK. AI-based voice assistant systems: Evaluating from the interaction and trust perspectives.
24. Dellermann D, Lipusch N, Ebel P, Leimeister JM. Design principles for a hybrid intelligence decision support system for business model validation. *Electronic markets*. 2019 Sep;29:423-41.
25. Kersting K. Machine learning and artificial intelligence: two fellow travelers on the quest for intelligent behavior in machines. *Frontiers in big Data*. 2018 Nov 19;1:6.
26. Rauschert S, Raubenheimer K, Melton PE, Huang RC. Machine learning and clinical epigenetics: a review of challenges for diagnosis and classification. *Clinical epigenetics*. 2020 Dec;12(1):1-1.
27. Bosse S, Maniry D, Müller KR, Wiegand T, Samek W. Deep neural networks for no-reference and full-reference image quality assessment. *IEEE Transactions on image processing*. 2017 Oct 10;27(1):206-19.
28. Mazzocco T, Hussain A. Novel logistic regression models to aid the diagnosis



- of dementia. *Expert Systems with Applications*. 2012 Feb 15;39(3):3356-61.
29. Lu J, Song E, Ghoneim A, Alrashoud M. Machine learning for assisting cervical cancer diagnosis: An ensemble approach. *Future Generation Computer Systems*. 2020 May 1;106:199-205.
30. Singh A, Mehta JC, Anand D, Nath P, Pandey B, Khamparia A. An intelligent hybrid approach for hepatitis disease diagnosis: Combining enhanced k-means clustering and improved ensemble learning. *Expert Systems*. 2021 Jan;38(1):e12526.
31. Goodfellow I, Bengio Y, Courville A. *Deep learning*. MIT press; 2016 Nov 10.
32. Fogassi L, Ferrari PF, Gesierich B, Rozzi S, Chersi F, Rizzolatti G. Parietal lobe: from action organization to intention understanding. *Science*. 2005 Apr 29;308(5722):662-7.
33. LeCun Y, Bengio Y, Hinton G. *Deep learning*. *nature*. 2015 May 28;521(7553):436-44.
34. Jain AK, Mao J, Mohiuddin KM. Artificial neural networks: A tutorial. *Computer*. 1996 Mar;29(3):31-44.
35. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. *Nature machine intelligence*. 2019 May;1(5):206-15.
36. Mishra S, Yamasaki T, Imaizumi H. Supervised classification of Dermatological diseases by Deep learning. arXiv preprint arXiv:1802.03752. 2018 Feb 11.
37. Jin, Y.; Qin, C.; Huang, Y.; Zhao, W.; Liu, C. Multi-domain modeling of atrial fibrillation detection with twin attentional convolutional long short-term memory neural networks. *Knowl.-Based Syst*. 2020, 193, 105460
38. Wong TT. Performance evaluation of classification algorithms by k-fold and leave-one-out cross validation. *Pattern recognition*. 2015 Sep 1;48(9):2839-46.
39. Ben-David A. Comparison of classification accuracy using Cohen's Weighted Kappa. *Expert Systems with Applications*. 2008 Feb 1;34(2):825-32.
40. Sokolova M, Lapalme G. A systematic analysis of performance measures for classification tasks. *Information processing & management*. 2009 Jul 1;45(4):427-37.
41. Prashanth R, Roy SD, Mandal PK, Ghosh S. High-accuracy detection of early Parkinson's disease through multimodal features and machine learning. *International journal of medical informatics*. 2016 Jun 1;90:13-21.
42. Wang H, Zhang D, Ding S, Gao Z, Feng J, Wan S. Rib segmentation algorithm for X-ray image based on

- unpaired sample augmentation and multi-scale network. *Neural Computing and Applications*. 2021 Sep 29;1-5.
43. Qaisar SM, Khan SI, Srinivasan K, Krichen M. Arrhythmia classification using multirate processing metaheuristic optimization and variational mode decomposition. *Journal of King Saud University-Computer and Information Sciences*. 2023 Jan 1;35(1):26-37.
44. Hrizi O, Gasmi K, Ben Ltaifa I, Alshammari H, Karamti H, Krichen M, Ben Ammar L, Mahmood MA. Tuberculosis disease diagnosis based on an optimized machine learning model. *Journal of Healthcare Engineering*. 2022 Mar 21;2022.
45. Stumpfe D, Bajorath J. Current trends, overlooked issues, and unmet challenges in virtual screening. *Journal of chemical information and modeling*. 2020 Feb 3;60(9):4112-5.
46. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow Jr RA, Fisher J, Jansen JM, Duca JS, Rush TS, Zentgraf M. Rethinking drug design in the artificial intelligence era. *Nature Reviews Drug Discovery*. 2020 May;19(5):353-64.
47. Boström J, Brown DG, Young RJ, Keserü GM. Expanding the medicinal chemistry synthetic toolbox. *Nature Reviews Drug Discovery*. 2018 Oct;17(10):709-27.
48. Strokach A, Becerra D, Corbi-Verge C, Perez-Riba A, Kim PM. Fast and flexible protein design using deep graph neural networks. *Cell systems*. 2020 Oct 21;11(4):402-11.
49. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. *Advanced drug delivery reviews*. 2019 Nov 1;151:169-90.
50. Yildirim O, Gottwald M, Schüller P, Michel MC. Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. *Frontiers in pharmacology*. 2016 Dec 6;7:461.
51. Nihar S, Nishith P, Patel KR. A sequential review on intelligent drug delivery system. *J. Pharm. Sci. Biosci. Res*. 2013;3(5):158-62.
52. Medarević DP, Kleinebudde P, Djuriš J, Djurić Z, Ibrić S. Combined application of mixture experimental design and artificial neural networks in the solid dispersion development. *Drug development and industrial pharmacy*. 2016 Mar 3;42(3):389-402.
53. Barmpalexis P, Koutsidis I, Karavas E, Louka D, Papadimitriou SA, Bikiaris DN. Development of PVP/PEG mixtures as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique and optimization of dissolution using artificial neural networks. *European Journal of Pharmaceutics and*

- Biopharmaceutics. 2013 Nov 1;85(3):1219-31.
54. Kumar KJ, Panpalia GM, Priyadarshini S. Application of artificial neural networks in optimizing the fatty alcohol concentration in the formulation of an O/W emulsion. *Acta Pharmaceutica*. 2011 Jun 1;61(2):249-56.
55. Gašperlin M, Podlogar F, Šibanc R. Evolutionary artificial neural networks as tools for predicting the internal structure of microemulsions. *Journal of Pharmacy & Pharmaceutical Sciences*. 2008 Mar 24;11(1):67-76.
56. Agatonovic-Kustrin S, Glass BD, Wisch MH, Alany RG. Prediction of a stable microemulsion formulation for the oral delivery of a combination of antitubercular drugs using ANN methodology. *Pharmaceutical research*. 2003 Nov;20:1760-5.
57. Petrović J, Ibrić S, Betz G, Đurić Z. Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees. *International journal of pharmaceutics*. 2012 May 30;428(1-2):57-67.
58. Mandal U, Gowda V, Ghosh A, Bose A, Bhaumik U, Chatterjee B, Pal TK. Optimization of metformin HCl 500 mg sustained release matrix tablets using Artificial Neural Network (ANN) based on Multilayer Perceptrons (MLP) model. *Chemical and Pharmaceutical Bulletin*. 2008 Feb 1;56(2):150-5.
59. Vaithiyalingam S, Khan MA. Optimization and characterization of controlled release multi-particulate beads formulated with a customized cellulose acetate butyrate dispersion. *International journal of pharmaceutics*. 2002 Mar 2;234(1-2):179-93.
60. Sankalia MG, Mashru RC, Sankalia JM, Sutariya VB. Papain entrapment in alginate beads for stability improvement and site-specific delivery: physicochemical characterization and factorial optimization using neural network modeling. *Aaps pharmscitech*. 2005 Jun;6:E209-22.
61. Deep Mind's health team. [cited 2022 13 June]; Available from: <https://www.deepmind.com/blog/deep-minds-healthteam-joins-google-health>.
62. IBM Watson for Oncology.; Available from: [https://www.ibm.com/common/ssi/cgi-bin/ssialias?appid=skmwww&htmlfid=897%2FENUS5725-W51&infotype=DD&subtype=SM&mhsrc=ibmsearch\\_a&mq=IBM%20WATSON%20ONcology#:~:text=IBM%20Watson%20for%20Oncology%2C%20software,Center%20physician%20and%20other%20analysts](https://www.ibm.com/common/ssi/cgi-bin/ssialias?appid=skmwww&htmlfid=897%2FENUS5725-W51&infotype=DD&subtype=SM&mhsrc=ibmsearch_a&mq=IBM%20WATSON%20ONcology#:~:text=IBM%20Watson%20for%20Oncology%2C%20software,Center%20physician%20and%20other%20analysts).
63. IBM. Medical Sieve. . [cited 2022 13 June]; Available from:

- [https://researcher.watson.ibm.com/researcher/view\\_group.php?id=4384](https://researcher.watson.ibm.com/researcher/view_group.php?id=4384).
64. MOLLY, THE VIRTUAL NURSE. [cited 2022 13 June]; Available from: <http://adigaskell.org/2015/03/20/meet-molly-the-virtual-nurse>
65. AiCure. THE RIGHT DOSE FOR THE RIGHT PATIENT. [cited 2022 13 June]; Available from: <https://aiculture.com/>.
66. Deep Genomics. Programming RNA Therapies Any Gene, Any Genetic Condition. [cited 2022 13 June]; Available from: <https://www.deepgenomics.com/>
67. Shampo MA, Kyle RA, J. Craig Venter—The Human Genome Project. In Mayo Clinic Proceedings 2011 Apr 1 (Vol. 86, No. 4, pp. e26-e27). Elsevier.
68. Atomwise. Artificial Intelligence for Drug Discovery.; Available from: <https://www.atomwise.com/>
69. Open AI Ecosystem.; Available from: <https://www.scientificamerican.com/article/open-ai-ecosystem-portends-a-personal-assistant-for-everyone/>.
70. invoicing in The Netherlands.; Available from: <https://ec.europa.eu/digital-buildingblocks/wikis/display/DIGITAL/eInvoicing+in+The+Netherlands>.
71. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Annals of the Royal College of Surgeons of England. 2004 Sep;86(5):334.
72. Albu A, Ungureanu L. Artificial neural network in medicine. Telemed. JE Health. 2012;18(6):446-53.
73. Jain AK, Mao J, Mohiuddin KM. Artificial neural networks: A tutorial. Computer. 1996 Mar;29(3):31-44.
74. Hopfield JJ. Artificial neural networks. IEEE Circuits and Devices Magazine. 1988 Sep;4(5):3-10.
75. Troulis MJ, Everett PE, Seldin EB, Kikinis R, Kaban LB. Development of a three-dimensional treatment planning system based on computed tomographic data. International journal of oral and maxillofacial surgery. 2002 Aug 1;31(4):349-357.
76. Arimura H, Soufi M, Kamezawa H, Ninomiya K, Yamada M. Radiomics with artificial intelligence for precision medicine in radiation therapy. Journal of radiation research. 2019 Jan 1;60(1):150-157.
77. Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunović H. Artificial intelligence in retina. Progress in retinal and eye research. 2018 Nov 1;67:1-29.
78. Hasani N, Paravastu SS, Farhadi F, Yousefirizi F, Morris MA, Rahmim A, Roschewski M, Summers RM, Saboury B. Artificial intelligence in lymphoma PET imaging: a scoping review (current trends and future directions). PET clinics. 2022 Jan 1;17(1):145-74.

79. Mitsala A, Tsalikidis C, Pitiakoudis M, Simopoulos C, Tsaroucha AK. Artificial intelligence in colorectal cancer screening, diagnosis and treatment. A new era. *Current Oncology*. 2021 Apr 23;28(3):1581-607.
80. Bang CS, Lee JJ, Baik GH. Artificial intelligence for the prediction of *Helicobacter pylori* infection in endoscopic images: systematic review and meta-analysis of diagnostic test accuracy. *Journal of medical Internet research*. 2020 Sep 16;22(9):e21983.
81. Liu Y. Artificial intelligence-assisted endoscopic detection of esophageal neoplasia in early stage: The next step?. *World Journal of Gastroenterology*. 2021 Apr 4;27(14):1392.
82. Zhang Z, He T, Huang L, Li J, Wang P. Immune gene prognostic signature for disease free survival of gastric cancer: Translational research of an artificial intelligence survival predictive system. *Computational and Structural Biotechnology Journal*. 2021 Jan 1;19:2329-46.
83. Yang YJ, Cho BJ, Lee MJ, Kim JH, Lim H, Bang CS, Jeong HM, Hong JT, Baik GH. Automated classification of colorectal neoplasms in white-light colonoscopy images via deep learning. *Journal of clinical medicine*. 2020 May 24;9(5):1593.
84. Posner MI, Rothbart MK. Research on attention networks as a model for the integration of psychological science. *Annu. Rev. Psychol.* 2007 Jan 10;58:1-23.
85. Haag, M.; Maylein, L.; Leven, F.J.; Tönshoff, B.; Haux, R. Web-based training: A new paradigm in computer-assisted instruction in medicine. *Int. J. Med. Inform.* 1999, 53, 79–90.
86. Li X, Liu H, Du X, Zhang P, Hu G, Xie G, Guo S, Xu M, Xie X. Integrated machine learning approaches for predicting ischemic stroke and thromboembolism in atrial fibrillation. *InAMIA Annual Symposium Proceedings 2016 (Vol. 2016, p. 799)*. American Medical Informatics Association.
87. Ellahham S. Artificial intelligence: the future for diabetes care. *The American journal of medicine*. 2020 Aug 1;133(8):895-900.
88. Prescott JH, Lipka S, Baldwin S, Sheppard Jr NF, Maloney JM, Coppeta J, Yomtov B, Staples MA, Santini Jr JT. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. *Nature biotechnology*. 2006 Apr;24(4):437-8.